1. Home
  2. CTMX vs RVPH Comparison

CTMX vs RVPH Comparison

Compare CTMX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • RVPH
  • Stock Information
  • Founded
  • CTMX 2008
  • RVPH 2006
  • Country
  • CTMX United States
  • RVPH United States
  • Employees
  • CTMX N/A
  • RVPH N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTMX Health Care
  • RVPH Health Care
  • Exchange
  • CTMX Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • CTMX 85.3M
  • RVPH 88.0M
  • IPO Year
  • CTMX 2015
  • RVPH N/A
  • Fundamental
  • Price
  • CTMX $0.83
  • RVPH $1.80
  • Analyst Decision
  • CTMX Buy
  • RVPH Strong Buy
  • Analyst Count
  • CTMX 6
  • RVPH 5
  • Target Price
  • CTMX $5.77
  • RVPH $11.40
  • AVG Volume (30 Days)
  • CTMX 785.3K
  • RVPH 1.5M
  • Earning Date
  • CTMX 03-10-2025
  • RVPH 11-14-2024
  • Dividend Yield
  • CTMX N/A
  • RVPH N/A
  • EPS Growth
  • CTMX N/A
  • RVPH N/A
  • EPS
  • CTMX 0.16
  • RVPH N/A
  • Revenue
  • CTMX $126,617,000.00
  • RVPH N/A
  • Revenue This Year
  • CTMX $22.55
  • RVPH N/A
  • Revenue Next Year
  • CTMX N/A
  • RVPH N/A
  • P/E Ratio
  • CTMX $4.97
  • RVPH N/A
  • Revenue Growth
  • CTMX 33.66
  • RVPH N/A
  • 52 Week Low
  • CTMX $0.75
  • RVPH $0.60
  • 52 Week High
  • CTMX $5.85
  • RVPH $4.59
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 44.23
  • RVPH 45.36
  • Support Level
  • CTMX $0.75
  • RVPH $1.97
  • Resistance Level
  • CTMX $0.98
  • RVPH $2.14
  • Average True Range (ATR)
  • CTMX 0.06
  • RVPH 0.16
  • MACD
  • CTMX 0.00
  • RVPH -0.02
  • Stochastic Oscillator
  • CTMX 33.17
  • RVPH 25.53

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: